$359m pro-forma cash! That's after tax amount.
2025 annual royalties will be around $65m.
Europe sales may come as early as Q2, 2025, expected to be approved in Q1, 2026.
Canada sales in Q3,2025.
Annual royalties for next year, is likely to reach $100m, imo.
Cash burn rate might not as high as I expected,
2024 R&D: $33m
Corporate & administrative: $4.7m
Total: $37.7m for the year.
- Forums
- ASX - By Stock
- NEU
- Ann: 2024 results - A$166m comprehensive income for shareholders
NEU
neuren pharmaceuticals limited
Add to My Watchlist
10.7%
!
$13.88

Ann: 2024 results - A$166m comprehensive income for shareholders, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.88 |
Change
1.340(10.7%) |
Mkt cap ! $1.728B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $7.175M | 526.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 343 | $13.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.88 | 69 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 181 | 13.850 |
6 | 439 | 13.840 |
2 | 339 | 13.830 |
3 | 1094 | 13.820 |
3 | 585 | 13.810 |
Price($) | Vol. | No. |
---|---|---|
13.870 | 312 | 2 |
13.880 | 175 | 3 |
13.890 | 228 | 3 |
13.900 | 404 | 3 |
13.910 | 1077 | 3 |
Last trade - 11.30am 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online